Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

74.79 -3.32 (-4.25%)
Official Closing Price Updated: 7:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,858,213
Open 74.32
Bid (Size) 75.20 (1)
Ask (Size) 75.50 (7)
Prev. Close 78.11
Today's Range 73.80 - 75.34
52wk Range 73.80 - 148.15
Shares Outstanding N/A
Dividend Yield 1.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool

Performance

YTD
-14.55%
-14.55%
1 Month
-10.87%
-10.87%
3 Month
-33.04%
-33.04%
6 Month
-44.69%
-44.69%
1 Year
-44.65%
-44.65%

More News

Read More
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Via Investor's Business Daily
NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information
From Robbins LLP
Via GlobeNewswire
Why Novo Nordisk Stock Is Falling Today
Via The Motley Fool
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Via Benzinga
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
Via Benzinga
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
The State of Weight Loss Drugs
Via The Motley Fool
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Via MarketBeat
Exposures Product Safety
3 Cold Stocks That Can Bounce Back This Week
Via The Motley Fool
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Via Investor's Business Daily
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
Via Benzinga
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Via Benzinga
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Via The Motley Fool
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Via Benzinga
Exposures Product Safety
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.